Bimatoprost SR is a medication used in this clinical trial to help lower the pressure inside the eye, known as intraocular pressure (IOP). This is important for patients with open-angle glaucoma or ocular hypertension, as high eye pressure can lead to vision problems or even blindness if not managed properly. The trial is testing the effectiveness and safety of Bimatoprost SR when given to patients, to see how well it works in reducing eye pressure and to ensure it is safe for use.

Ocular Hypertension – Ocular hypertension occurs when the pressure inside the eye, known as intraocular pressure, is higher than normal. This condition does not cause any noticeable symptoms, and vision remains unaffected initially. However, if left unchecked, it can lead to damage to the optic nerve, potentially resulting in glaucoma. Regular eye examinations are crucial to monitor and manage this condition effectively. It is important to differentiate ocular hypertension from glaucoma, as the latter involves optic nerve damage and vision loss.

Open-Angle Glaucoma – Open-angle glaucoma is a chronic eye condition characterized by a gradual increase in intraocular pressure, leading to damage to the optic nerve. This type of glaucoma is the most common form and progresses slowly, often without noticeable symptoms in the early stages. As the disease advances, peripheral vision is typically affected first, and if untreated, it can lead to significant vision loss. The “open-angle” refers to the angle between the iris and cornea, which remains open, but the drainage canals become less efficient over time. Regular eye check-ups are essential for early detection and management.